IFN-α and novel strategies of combination therapy for cancer

Annals of the New York Academy of Sciences

Volumn 1112, Issue , 2007, Pages 256-268

  Bracci, Laura ^a   Proietti, Enrico ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Chemotherapy; IFN ; Immunotherapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; INTERFERON; THYMOSIN ALPHA1;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ACTIVITY; CELL INTERACTION; CONFERENCE PAPER; DENDRITIC CELL; DISEASE MODEL; DRUG MECHANISM; GENE THERAPY; GENE TRANSFER; HOST; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; T LYMPHOCYTE;

EID: 35348960343     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1415.030     Document Type: Conference Paper

References (53)

1. VILCEK, J. 2006. Fifty years of interferon research: aiming at a moving target. Immunity 25: 343-348.
2. BELARDELLI, F. & I. GRESSER. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17: 369-372.
3. FERRANTINI, M. & F. BELARDELLI. 2000. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10: 145-157.
4. FERRANTINI, M. et al. 1993. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 53: 1107-1112.
5. GABRIELE, L. et al. 1995. Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells. Am. J. Pathol. 147: 445-460.
6. FERRANTINI, M. et al. 1994. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J. Immunol. 153: 4604-4615.
7. ROZERA, C. et al. 1999. Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy. Cancer Gene. Ther. 6: 246-253.
8. BELARDELLI, F. et al. 1998. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res. 58: 5795-5802.
9. BELARDELLI, F. et al. 2002. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 119-134.
10. TOUGH, D.F., P. BORROW & J. SPRENT. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950.
11. SUN, S. et al. 1998. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188: 2335-2342.
12. MARRACK, P., J. KAPPLER & T. MITCHELL. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189: 521-530.
13. MATIKAINEN, S. et al. 1999. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93: 1980-1991.
14. SIEGAL, F.P. et al. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837.
15. CELLA, M. et al. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5: 919-923.
16. CELLA, M., F. SALLUSTO & A. LANZAVECCHIA. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9: 10-16.
17. STEINMAN, R.M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296.
18. BELARDELLI, F. et al. 2004. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. 64: 6827-6830.
19. LUFT, T. et al. 1998. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161: 1947-1953.
20. PAQUETTE, R.L. et al. 1998. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64: 358-367.
21. SANTINI, S.M. et al. 2000. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191: 1777-1788.
22. LAPENTA, C. et al. 2003. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J. Exp. Med. 198: 361-367.
23. SANTODONATO, L. et al. 2003. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. J. Immunol. 170: 5195-5202.
24. TOSI, D. et al. 2004. Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J. Immunol. 172: 5363-5370.
25. LAPENTA, C. et al. 2006. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 36: 2046-2060.
26. LE BON, A. et al. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
27. PROIETTI, E. et al. 2002. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169: 375-383.
28. BANCHEREAU, J. & V. PASCUAL. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
29. BLANCO, P. et al. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540-1543.
30. HAKANSSON, A. et al. 1996. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br. J. Cancer 74: 670-676.
31. HAKANSSON, A. et al. 1998. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J. Interferon Cytokine Res. 18: 33-39.
32. MOLLDREM, J.J. et al. 2000. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6: 1018-1023.
33. WU, C.J. et al. 2000. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J. Clin. Invest. 106: 705-714.
34. WANG, C. et al. 1999. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha. Exp. Hematol. 27: 1176-1184.
35. GABRIELE, L. et al. 2004. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 103: 980-987.
36. CHEN, X. et al. 2000. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br. J. Haematol. 111: 596-607.
37. GOGAS, H. et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354: 709-718.
38. KOON, H. & M. ATKINS. 2006. Autoimmunity and immunotherapy for cancer. N. Engl. J. Med. 354: 758-760.
39. DI PUCCHIO, T. et al. 2006. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res. 66: 4943-4951.
40. SINKOVICS, J.G. & J.C. HORVATH. 2006. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int. J. Oncol. 29: 765-777.
41. AWWAD, M. & R.J. NORTH. 1988. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65: 87-92.
42. GARACI, E. et al. 1990. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol. Immunother. 32: 154-160.
43. GARACI, E. et al. 1993. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J. Immunother. 13: 7-17.
44. EMENS, L.A. & E.M. JAFFEE. 2005. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65: 8059-8064.
45. GORELIK, L., A. PROKHOROVA & M.B. MOKYR. 1994. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother. 39: 117-126.
46. MATAR, P. et al. 2002. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother. 50: 588-596.
47. BRACCI, L. et al. 2007. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13: 644-653.
48. PROIETTI, E. et al. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101: 429-441.
49. SCHIAVONI, G. et al. 2000. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
50. SALEM, M.L. et al. 2007. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30: 40-53.
51. BYRD-LEIFER, C.A. et al. 2001. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur. J. Immunol. 31: 2448-2457.
52. EMENS, L.A. et al. 2001. Chemotherapy: friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 3: 77-84.
53. GHIRINGHELLI, F. et al. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.